Do analysts recommend CYCN or SBFM?

Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 6,696.12%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Sunshine Biopharma (SBFM) Competitors

$1.04 +0.02 (+1.46%)

As of 10:02 AM Eastern

Compare

SBFM vs. ADIL, CTXR, CYCN, SCNX, and MBRX

Should you buy Sunshine Biopharma stock or one of its competitors? Sunshine Biopharma's main competitors and comparable companies include Adial Pharmaceuticals (ADIL), Citius Pharmaceuticals (CTXR), Cyclerion Therapeutics (CYCN), Scienture (SCNX), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sunshine Biopharma compare to Adial Pharmaceuticals?

Sunshine Biopharma (NASDAQ:SBFM) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Sunshine Biopharma has higher revenue and earnings than Adial Pharmaceuticals. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.11	-$5.97M	-$10.15	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

Sunshine Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adial Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Sunshine Biopharma currently has a consensus price target of $70.00, suggesting a potential upside of 6,696.12%. Adial Pharmaceuticals has a consensus price target of $15.63, suggesting a potential upside of 209.77%. Given Sunshine Biopharma's higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 1 articles in the media. Sunshine Biopharma's average media sentiment score of 1.91 beat Adial Pharmaceuticals' score of 1.89 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Very Positive
Adial Pharmaceuticals	Very Positive

Summary

Sunshine Biopharma beats Adial Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Sunshine Biopharma (NASDAQ:SBFM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Citius Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.94%	-26.36%	-20.60%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 1.91 beat Citius Pharmaceuticals' score of 0.94 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Very Positive
Citius Pharmaceuticals	Positive

Sunshine Biopharma has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.11	-$5.97M	-$10.15	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sunshine Biopharma has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

Sunshine Biopharma presently has a consensus target price of $70.00, indicating a potential upside of 6,696.12%. Citius Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 777.19%. Given Sunshine Biopharma's higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Sunshine Biopharma beats Citius Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 6,696.12%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sunshine Biopharma has a net margin of -17.94% compared to Cyclerion Therapeutics' net margin of -170.11%. Sunshine Biopharma's return on equity of -26.36% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for Cyclerion Therapeutics and 1 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 1.91 beat Cyclerion Therapeutics' score of 0.58 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclerion Therapeutics	Positive
Sunshine Biopharma	Very Positive

Cyclerion Therapeutics has higher earnings, but lower revenue than Sunshine Biopharma. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A
Sunshine Biopharma	$36.31M	0.11	-$5.97M	-$10.15	N/A

Cyclerion Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Summary

Sunshine Biopharma beats Cyclerion Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sunshine Biopharma compare to Scienture?

Scienture (NASDAQ:SCNX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Sunshine Biopharma has higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	31.65	-$41.51M	-$2.10	N/A
Sunshine Biopharma	$36.31M	0.11	-$5.97M	-$10.15	N/A

Scienture presently has a consensus target price of $1.50, indicating a potential upside of 352.49%. Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 6,696.12%. Given Sunshine Biopharma's higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Scienture.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Scienture had 2 more articles in the media than Sunshine Biopharma. MarketBeat recorded 3 mentions for Scienture and 1 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 1.91 beat Scienture's score of 0.72 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Scienture	Positive
Sunshine Biopharma	Very Positive

Scienture has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

5.7% of Scienture shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 21.4% of Scienture shares are held by company insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scienture has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

Summary

Sunshine Biopharma beats Scienture on 8 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to Moleculin Biotech?

Moleculin Biotech (NASDAQ:MBRX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Moleculin Biotech currently has a consensus target price of $3.00, suggesting a potential upside of 289.61%. Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 6,696.12%. Given Sunshine Biopharma's higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Moleculin Biotech had 5 more articles in the media than Sunshine Biopharma. MarketBeat recorded 6 mentions for Moleculin Biotech and 1 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 1.91 beat Moleculin Biotech's score of 0.39 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Moleculin Biotech	Neutral
Sunshine Biopharma	Very Positive

Moleculin Biotech has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 18.0% of Moleculin Biotech shares are held by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Moleculin Biotech has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.94%. Sunshine Biopharma's return on equity of -26.36% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-143.51%	-24.53%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

Sunshine Biopharma has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A
Sunshine Biopharma	$36.31M	0.11	-$5.97M	-$10.15	N/A

Summary

Sunshine Biopharma beats Moleculin Biotech on 8 of the 15 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.15M	$12.42B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.57%	12.21%
P/E Ratio	-0.10	789.61	272.86	25.31
Price / Sales	0.11	951.39	706.15	112.46
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	0.02	10.39	10.44	6.18
Net Income	-$5.97M	$2.83B	$3.49B	$357.96M
7 Day Performance	-8.04%	-1.54%	-0.76%	-0.56%
1 Month Performance	-10.43%	0.78%	-0.38%	-3.62%
1 Year Performance	-93.09%	3.89%	18.93%	6.05%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	2.9413 of 5 stars	$1.05 +1.5%	$70.00 +6,598.6%	-93.0%	$4.06M	$36.31M	N/A	3	News Coverage Positive News
ADIL Adial Pharmaceuticals	3.1005 of 5 stars	$6.30 -5.3%	$15.63 +148.1%	-42.9%	$16.57M	N/A	N/A	20	Positive News
CTXR Citius Pharmaceuticals	2.4573 of 5 stars	$0.59 -1.2%	$5.00 +743.2%	-50.9%	$16.47M	N/A	N/A	20
CYCN Cyclerion Therapeutics	1.109 of 5 stars	$3.49 +3.9%	N/A	-78.9%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
SCNX Scienture	3.0256 of 5 stars	$0.38 +4.8%	$1.50 +293.7%	-66.3%	$15.40M	$430K	N/A	N/A	Short Interest Decrease Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. ADIL, CTXR, CYCN, SCNX, and MBRX

How does Sunshine Biopharma compare to Adial Pharmaceuticals?

Summary

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Summary

How does Sunshine Biopharma compare to Cyclerion Therapeutics?

Summary

How does Sunshine Biopharma compare to Scienture?

Summary

How does Sunshine Biopharma compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. ADIL, CTXR, CYCN, SCNX, and MBRX

How does Sunshine Biopharma compare to Adial Pharmaceuticals?

Which has stronger valuation and earnings, SBFM or ADIL?

Which has more volatility & risk, SBFM or ADIL?

Do institutionals & insiders believe in SBFM or ADIL?

Is SBFM or ADIL more profitable?

Do analysts rate SBFM or ADIL?

Does the media prefer SBFM or ADIL?

Summary

How does Sunshine Biopharma compare to Citius Pharmaceuticals?

Is SBFM or CTXR more profitable?

Does the media refer more to SBFM or CTXR?

Which has stronger earnings and valuation, SBFM or CTXR?

Do insiders and institutionals believe in SBFM or CTXR?

Which has more risk and volatility, SBFM or CTXR?

Do analysts prefer SBFM or CTXR?

Summary

How does Sunshine Biopharma compare to Cyclerion Therapeutics?

Do insiders and institutionals hold more shares of CYCN or SBFM?

Do analysts recommend CYCN or SBFM?

Is CYCN or SBFM more profitable?

Does the media prefer CYCN or SBFM?

Which has preferable valuation & earnings, CYCN or SBFM?

Which has more risk & volatility, CYCN or SBFM?

Summary

How does Sunshine Biopharma compare to Scienture?

Which has higher earnings & valuation, SCNX or SBFM?

Do analysts recommend SCNX or SBFM?

Does the media favor SCNX or SBFM?

Which has more volatility and risk, SCNX or SBFM?

Do insiders & institutionals have more ownership in SCNX or SBFM?

Is SCNX or SBFM more profitable?

Summary

How does Sunshine Biopharma compare to Moleculin Biotech?

Do analysts prefer MBRX or SBFM?

Does the media prefer MBRX or SBFM?

Which has more volatility & risk, MBRX or SBFM?

Do insiders & institutionals hold more shares of MBRX or SBFM?

Is MBRX or SBFM more profitable?

Which has higher valuation and earnings, MBRX or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools